potassium voltage-gated channel subfamily Q member 1
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The KCNQ1 gene belongs to a large family of genes that provide instructions for making potassium channels. These channels, which transport positively charged atoms (ions) of potassium out of cells, play key roles in a cell's ability to generate and transmit electrical signals.
Video picks for GenesVideo library
Normal function
The KCNQ1 gene belongs to a large family of genes that provide instructions for making potassium channels. These channels, which transport positively charged atoms (ions) of potassium out of cells, play key roles in a cell's ability to generate and transmit electrical signals.
The specific function of a potassium channel depends on its protein components and its location in the body. Channels made with KCNQ1 proteins are primarily found in the inner ear and in heart (cardiac) muscle. In the inner ear, these channels help maintain the proper ion balance needed for normal hearing. In the heart, the channels are involved in recharging the cardiac muscle after each heartbeat to maintain a regular rhythm. The KCNQ1 protein is also produced in the kidney, lung, stomach, and intestine.
The KCNQ1 protein interacts with proteins in the KCNE family (such as the KCNE1 protein) to form functional potassium channels. Four alpha subunits made from KCNQ1 proteins form the structure of each channel. One beta subunit, made from a KCNE protein, attaches (binds) to the channel and regulates its activity.
Conditions referring to this gene or chromosome
Other names
ATFB1
IKs producing slow voltage-gated potassium channel alpha subunit KvLQT1
JLNS1
KCNA8
KCNA9
KCNQ1_HUMAN
KQT-like 1
Kv1.9
Kv7.1
KVLQT1
LQT1
potassium channel, voltage gated KQT-like subfamily Q, member 1
potassium voltage-gated channel, KQT-like subfamily, member 1
Patient picks for Genes

Treatment and medication
Potassium-sparing diuretics
Diuretics are medicines which increase the amount of fluid removed from the body when we pass urine. Potassium-sparing diuretics are one type of diuretic. They are weak diuretics usually prescribed in combination with other types of diuretics. They are used to increase the amount of fluid passed from the body in urine, whilst also preventing too much potassium being lost with it. Side-effects are uncommon when routine low doses are used. Most people are able to take these medicines.
by Dr Doug McKechnie, MRCGP

Drug interactions checker
Can I take Lisinopril and Potassium together?
Taking lisinopril and potassium supplements together can cause the levels of potassium in your blood to become dangerously high (a condition called hyperkalaemia). While your body needs potassium for your heart and muscles to work, too much of it can lead to serious heart rhythm problems or even cause the heart to stop. Symptoms of high potassium can include muscle weakness, tingling sensations, or palpitations, but often there are no symptoms until the level is very high.

Mental health
Mind and body control - how to channel your ‘internal telekinesis’
The dark nights have arrived, and right on cue, Mike Flanagan has turned his attention to one of Stephen King’s most iconic tales of teenage torment and supernatural terror... Carrie. The story of a schoolgirl with telekinetic powers - the fictional ability to move objects using the mind alone - has gripped our morbid imaginations for decades. Little wonder, then, that this horror classic is getting a new lease of life in a television adaptation. But while we ourselves may not be able to bend spoons or move furniture, we do possess our own real-world form of ‘internal-telekinesis’. Through mental focus and controlled breathing, we can influence our heart rate and help calm an overworked nervous system.
by Hannah Boynton-Forshaw

Drug interactions checker
Can I take Spironolactone and Potassium together?
Taking spironolactone and potassium supplements together can lead to dangerously high levels of potassium in your blood (a condition called hyperkalaemia). While your body needs potassium for your heart and muscles to work, too much of it can cause serious heart rhythm problems or even cause the heart to stop beating. Symptoms of high potassium can include muscle weakness, tingling sensations, or palpitations, but often there are no symptoms until the level is very high.

Healthy living
Dietary potassium
Potassium is a mineral found naturally in many foods. It is needed in the body for the normal functioning of the heart, nerves and muscles. High potassium levels can lead to dangerous heart rhythms. Low potassium levels can cause muscle weakness and problems with the heart rhythm too. Long-term low levels of potassium has been linked to high blood pressure, heart disease, and stroke. Low potassium is particularly likely to raise your blood pressure if you have a high intake of salt (sodium chloride). Potassium relaxes the walls of the blood vessels, lowering blood pressure. It also protects against muscle cramping.
by Dr Surangi Mendis, MRCGP

Treatment and medication
Calcium channel blockers
Calcium channel blockers (sometimes called calcium antagonists) are a group of medicines that affect the way calcium passes into certain muscle cells. They are commonly prescribed to manage high blood pressure, angina, Raynaud's phenomenon and some abnormal heart rhythms (arrhythmias). They are also used to try to stop premature labour in pregnancy. A calcium-channel blocker can be used alone. However, one is often combined with another medicine to treat high blood pressure or angina, when one medicine alone has not worked so well.
by Dr Toni Hazell, FRCGP
Related patient information and medicines

Patient information leaflet
Angina
Angina is a pain that comes from the heart. It is usually caused by narrowing of the heart's blood vessels - the (coronary) arteries. What is angina. Dr Yassir Javid Angina is a pain that comes from the heart. It is usually caused by narrowing of the heart (coronary) arteries. Sometimes angioplasty or surgery are opt... For more information on.

Patient information leaflet
Acute kidney injury
Acute kidney injury can be a confusing name as it suggests an accident or injury to that part of your body, eg from a fall or trauma. However, acute kidney injury is actually a condition where your kidneys suddenly stop working properly. If you have acute kidney injury (AKI) your kidneys suddenly stop working as well as they should. This means the.

Patient information leaflet
6-in-1 vaccine
The 6-in-1 vaccine is part of routine childhood immunisations and protects babies against six different serious illnesses. Three doses are given. Further boosters without all six components are given at other times later in childhood and in adult life. The 6-in-1 vaccine used to be given as the 3-in-1 vaccine DTaP along with the polio vaccine.

Patient information leaflet
Can I take Magnesium and Flecainide together?
In some cases, magnesium can actually be helpful for heart rhythm issues, but it must be balanced correctly. Why this happens Both magnesium and flecainide affect the electrical signals and mineral channels (like sodium and potassium) in your heart cells. While they don't usually stop each other from being absorbed, having too much or too little.

Patient information leaflet
Loop diuretics
Loop diuretics are commonly used in the treatment of heart failure. In this condition, fluid accumulates in your body, due to the heart not pumping blood around the body as well as it normally would. So, you may become breathless (as fluid accumulates in the lungs) and your ankles and legs may swell with extra fluid in the tissues (oedema). Loop.

Patient information leaflet
Medicine for high blood pressure
For detailed information about your own medication you should read the leaflet that comes inside the medicine packet. What are the types of blood pressure medicines. There are six main classes of medicines that are used to lower blood pressure: Angiotensin-converting enzyme (ACE) inhibitors. Angiotensin receptor blockers (ARBs). Calcium-channel.
Further reading and references
- potassium voltage-gated channel subfamily Q member 1; MedlinePlus, National Library of Medicine.
- Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Wang DW, Rhodes TE, George AL Jr, Schwartz PJ. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007 Jan 23;115(3):361-7. doi: 10.1161/CIRCULATIONAHA.106.658021. Epub 2007 Jan 8.
- Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, Baro I, Wilde AA. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004 May 25;109(20):2394-7. doi: 10.1161/01.CIR.0000130409.72142.FE.
- Chan PJ, Osteen JD, Xiong D, Bohnen MS, Doshi D, Sampson KJ, Marx SO, Karlin A, Kass RS. Characterization of KCNQ1 atrial fibrillation mutations reveals distinct dependence on KCNE1. J Gen Physiol. 2012 Feb;139(2):135-44. doi: 10.1085/jgp.201110672. Epub 2012 Jan 16.
- Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA. Mutations in the long QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. Heart. 2004 Dec;90(12):1487-8. doi: 10.1136/hrt.2003.027227. No abstract available.
- Faridi R, Przybylski R, Saenen J, Hertzano R, Newman WG, Friedman TB. Jervell and Lange-Nielsen Syndrome. 2002 Jul 29 [updated 2026 Oct 15]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1405/
- Groffen AJ, Bikker H, Christiaans I. Long QT Syndrome Overview. 2003 Feb 20 [updated 2024 Mar 21]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1129/
- Herbert E, Trusz-Gluza M, Moric E, Smilowska-Dzielicka E, Mazurek U, Wilczok T. KCNQ1 gene mutations and the respective genotype-phenotype correlations in the long QT syndrome. Med Sci Monit. 2002 Oct;8(10):RA240-8.
- Hong K, Piper DR, Diaz-Valdecantos A, Brugada J, Oliva A, Burashnikov E, Santos-de-Soto J, Grueso-Montero J, Diaz-Enfante E, Brugada P, Sachse F, Sanguinetti MC, Brugada R. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res. 2005 Dec 1;68(3):433-40. doi: 10.1016/j.cardiores.2005.06.023. Epub 2005 Aug 18.
- Huang L, Bitner-Glindzicz M, Tranebjaerg L, Tinker A. A spectrum of functional effects for disease causing mutations in the Jervell and Lange-Nielsen syndrome. Cardiovasc Res. 2001 Sep;51(4):670-80. doi: 10.1016/s0008-6363(01)00350-9.
- Ioakeimidis NS, Papamitsou T, Meditskou S, Iakovidou-Kritsi Z. Sudden infant death syndrome due to long QT syndrome: a brief review of the genetic substrate and prevalence. J Biol Res (Thessalon). 2017 Mar 14;24:6. doi: 10.1186/s40709-017-0063-1. eCollection 2017 Dec.
- Jespersen T, Grunnet M, Olesen SP. The KCNQ1 potassium channel: from gene to physiological function. Physiology (Bethesda). 2005 Dec;20:408-16. doi: 10.1152/physiol.00031.2005.
- Melman YF, Um SY, Krumerman A, Kagan A, McDonald TV. KCNE1 binds to the KCNQ1 pore to regulate potassium channel activity. Neuron. 2004 Jun 24;42(6):927-37. doi: 10.1016/j.neuron.2004.06.001.
- Park KH, Piron J, Dahimene S, Merot J, Baro I, Escande D, Loussouarn G. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome. Circ Res. 2005 Apr 15;96(7):730-9. doi: 10.1161/01.RES.0000161451.04649.a8. Epub 2005 Mar 3.
- Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl). 2004 Mar;82(3):182-8. doi: 10.1007/s00109-003-0522-z. Epub 2004 Feb 4.
- Tristani-Firouzi M, Sanguinetti MC. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J Mol Cell Cardiol. 2003 Jan;35(1):27-35. doi: 10.1016/s0022-2828(02)00286-9.
- Wang Z, Li H, Moss AJ, Robinson J, Zareba W, Knilans T, Bowles NE, Towbin JA. Compound heterozygous mutations in KvLQT1 cause Jervell and Lange-Nielsen syndrome. Mol Genet Metab. 2002 Apr;75(4):308-16. doi: 10.1016/S1096-7192(02)00007-0.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

